- Genprex, a clinical stage gene therapy company, will be utilizing the services of a leading pharmaceutical branding agency to oversee the naming process of its lead drug candidate, Oncoprex
- Addison Whitney has over 28 years of experience in the market, guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps involved in the name approval process
- Oncoprex is an innovative immunogene therapy targeting non-small cell lung cancer
Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, recently reported that it has retained the services of leading pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://ibn.fm/ci3KJ).
The move will enable Genprex to pursue the commercialization of Oncoprex immunogene therapy, which is currently in development and undergoing a clinical trial for the treatment of non-small cell lung cancer (NCSLC).
Addison Whitney will draw from its 28 years of market experience to oversee the proprietary and non-proprietary naming process for Genprex’s leading drug candidate.
Addison Whitney has a proven track record of branding success within the pharmaceutical market. It enables clients to achieve growth through both brand differentiation and creative naming practices. Its most recent successes include guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps needed for name approval.
According to Genprex Chairman and CEO Rodney Varner, retaining the services of Addison Whitney is an important step in bringing Oncoprex to market. Obtaining regulatory approval for the proprietary and non-proprietary drug names is one of the essentials for securing market approval, he explained. Varner said that he believes that Addison Whitney has an excellent reputation when it comes to securing such name approvals.
Currently, Genprex is carrying out a phase I/II clinical trial of Oncoprex in combination with erlotinib, treating NSCLC. Additionally, preclinical studies are underway to evaluate the effectiveness of Oncoprex in combination with immunotherapies.
Oncoprex works by interrupting the cell signaling pathways that contribute to the replication of cancer cells. It also stimulates the natural immune response against cancer. Oncoprex consists of TUSC2 – a tumor suppressor gene – encapsulated in a lipid nanoparticle. When injected intravenously, it specifically targets cancer cells, where the tumor suppressor gene is taken up and expressed in a protein that restores some of the defective gene functions arising in cancer cells.
Lung cancer is the leading cause of cancer deaths across the world, killing more people than breast, colon, kidney, liver, prostate and skin cancers combined. While newly diagnosed lung cancer cases have remained at steady annual levels among men, an increase of over 40 percent in new diagnoses is expected in women by 2030 (http://ibn.fm/p7BVD). In comparison, the global standardized breast cancer mortality rate among women is expected to go down nine percent within the same period.
Companies like Genprex are leading the way in identifying, researching and developing innovative treatment options. Genprex holds a portfolio of more than 30 patents for its platform technologies. In addition, it’s currently working on pinpointing the biomarkers that will help the selection of patients who will benefit the most from the Genprex treatments.
For more information, visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.